FDA Okays First Targeted Agent for HER2-Low Breast CancerThe targeted therapy led to longer progression-free and overall survival compared with chemotherapy. FDA Approvalsadminagosto 6, 2022Uncategorized The targeted therapy led to longer progression-free and overall survival compared with chemotherapy. FDA Approvals